Botanicals regulation as supplements, not OTCs, clarified by commission.
This article was originally published in The Tan Sheet
Executive Summary
BOTANICAL SUBSTANCE "EN MASSE" REGULATORY CONSIDERATION AS OTCs was not the intent of the President's Commission on Dietary Supplement Labels, commission Chairman Malden Nesheim, PhD, Cornell University, clarified at the group's Aug. 14-15 review of comments received on its draft report in Reston, Va. In its June 24 draft report, the commission proposed that FDA establish "an OTC review panel for botanical products that are intended for therapeutic and preventive use, with appropriate representation of experts on such products" ("The Tan Sheet" June 30, pp. 17-25).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning